Search Results
Your search for ,wAs matches 27466 pages
Showing 15201 - 15250A Love of Science Leads to an Esteemed Career in Cancer Research for Razelle Kurzrock, MD
Razelle Kurzrock, MD, regarded internationally for her work in translational science, was born and reared in Toronto, Canada. “My parents were immigrants from Eastern Europe. My father, who was Jewish, was a Holocaust survivor. My parents put a strong emphasis on education,” she said. ‘The...
FDA Oncology Drug Approvals Granted Between June 2017 and May 16, 2018
Over the past year (June 2017–May 2018), the U.S. Food and Drug Administration (FDA) granted approval to a number of new oncology drug products, including several biosimilar products. Here we provide the labeling approved for these novel drugs and new indications. EPOETIN ALFA-EPBX (RETACRIT)...
A Love of Older Patients With Cancer Drives a Career Path for Arti Hurria, MD, FASCO
Arti Hurria, MD, FASCO, who is Director of City of Hope’s Center for Cancer and Aging, is a first generation of immigrant parents from India. “My parents left India and moved from England to Canarsie, Brooklyn, where I was born. When I was 8, my family moved to Southern California, partly due to...
Pioneer in Genitourinary Oncology, José R. Germà-Lluch, MD, PhD, Sheds Light on Treating Rare Tumors
“At the age of 6, my mother threw me into the arms of Hippocrates’ discipline, giving me as a special gift a toy suitcase full of medical equipment and a little puppet to train my skills with a stethoscope, syringe, thermometer, small reflex hammer, and torch to explore the oropharyngeal airways....
Husband and Wife Leave a Giant Legacy in Oncology
The remarkable careers of Jimmie C. Holland, MD, and James F. Holland, MD, spanned collectively for more than a century, leaving an indelible footprint in oncology clinical care and research. Synonymous with cancer care itself, the Hollands were a living documentary of the rich and dramatic history ...
International Oncologist Nagi S. El Saghir, MD, FACP, Returned Home to Make a Difference in Lebanon and Worldwide
Internationally renowned expert on the early detection, prevention, and treatment of younger women with breast cancer, Nagi S. El Saghir, MD, FACP, FASCO, was born on January 5, 1953, in Bint Jbeil, a village in southern Lebanon. His parents moved to Beirut in 1948, at the height of the...
Pioneering Researcher and Oncologist Volker S. Diehl, MD, Helped Unlock the ‘Black Box’ of Hodgkin Lymphoma
Volker S. Diehl, MD, the internationally renowned hematologist and researcher, was born in Berlin, Germany, on February 28, 1938—arguably one of the most tumultuous periods in world history. Germany had just invaded Austria, signaling the dark intentions of the Third Reich. In 1943, the air raids...
AUA 2018: Is Prostate Cancer Screening and Risk Stratification Moving Beyond the PSA Test?
New diagnostic tests for prostate cancer, as well as new information about the impact of the U.S. Preventive Services Task Force recommendations on prostate cancer screening, were presented at the 113th Annual Meeting of the American Urological Association (AUA). PSA Screening of African American...
AUA 2018: Apalutamide Significantly Reduced Risk of PSA Progression in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
A post-hoc analysis from the phase III SPARTAN study that showed treatment with apalutamide (Erleada) significantly reduced the risk of prostate-specific antigen (PSA) progression in patients with nonmetastatic castration-resistant prostate cancer (CRPC) who had a rapidly rising PSA while receiving ...
AUA 2018: Use of MRI for Prostate Cancer Screening and Management
Use of magnetic resonance imaging (MRI) in the diagnosis of prostate cancer is increasing and brings added value to screening and surveillance, according to new studies presented this year during the 113th Annual Meeting of the American Urological Association (AUA). Four studies highlighting the...
AUA 2018: Panel Discusses New Research on Prostate Cancer Management Protocols and Treatments
Researchers presented new findings on a Korean Food and Drug Administration (KFDA)-approved robotic system, safety of testosterone therapy after prostate cancer, and active surveillance protocol for low-risk prostate cancer patients at the 113th Annual Meeting of the American Urological Association ...
AUA 2018: More Than 40% of Prostate Biopsies May Have Been Avoided With Use of Assay for Detection
A multicenter study that validated the clinical performance of IsoPSA—a new blood test that has proven to be more accurate in predicting overall risk of prostate cancer than standard prostate-specific antigen (PSA)—was presented at the 13th Annual Meeting of the American Urological...
Risk-Prediction Tool Helps Tailor Lung Cancer Screening to Patient Preference and Clinical Benefit
A microsimulation model study found that the benefits of low-dose computed tomography (CT) screening for lung cancer varied substantially across the eligible population, with 3 factors being particularly influential: lung cancer risk, competing risks or life expectancy, and patient...
ASCO Launches Its Education Scholars Program
Education is such an integral part of ASCO’s strategic plan to reduce the burden of cancer for all patients, it is incorporated into the Society’s mission statement to “conquer cancer through research, education, and promotion of the highest patient care.” In 2017, ASCO’s Board of Directors voted...
Risk of Recurrence in Stage III Colon Cancer According to RAS- and BRAF-Mutation Status
In a study in the PETACC-8 trial population reported in JAMA Oncology, Julien Taieb, MD, PhD, of the Université Paris Descartes, and colleagues found that the risk of recurrence in patients with stage III colon cancer differed for the primary tumor location according to RAS- and BRAF-mutation...
Number of Metastatic Lymph Nodes and Survival in Hypopharyngeal/Laryngeal Cancer
A study using National Cancer Database data has shown that the number of metastatic nodes is a primary independent factor associated with an increased mortality risk in patients with hypopharyngeal and laryngeal cancers. The study was reported in JAMA Oncology by Allen S. Ho, MD, of the Samuel...
Tumor-Infiltrating Lymphocytes and Prognosis in Breast Cancer Subtypes
In a study reported in The Lancet Oncology by Denkert and colleagues, increased levels of tumor-infiltrating lymphocytes (TILs) in women receiving neoadjuvant chemotherapy were associated with improved prognosis in HER2-positive and triple-negative breast cancers but poorer outcome in luminal...
Hormonal Contraception and Breast Cancer Risk
As reported in The New England Journal of Medicine by Lina S. Mørch, PhD, of the University of Copenhagen, and colleagues, a Danish study has shown that the risk of breast cancer is increased in hormonal contraception users vs nonusers, with the absolute increase in risk being small. The study...
American Cancer Society Awards New Research and Training Grants
THE AMERICAN CANCER Society has approved funding for 110 grants totaling $47,624,000 to researchers and health professionals across 72 institutions nationwide in the first of 2 grant cycles for 2018. Of these grants, 101 are new and 9 are renewals of previous grants. Two individuals have been...
Stage IV Lung Cancer Did Not Stop Me From Climbing Mera Peak
A veteran mountain climber and skier, I’ve been healthy for most of my 61 years, so it was especially shocking to experience a bout of shortness of breath during a moderately intense mountain bike ride with my wife, Jan, in the spring of 2014. A never-smoker, I was used to climbing up high mountain ...
Study Finds Mutated Tau May Be a Susceptibility Factor for Cancer
Tau proteins perform the function of stabilizing microtubules, a major element of the eukaryotic cytoskeleton. Traditionally associated with neurodegeneration, tau also has a role in the maintenance of genome stability and chromosome integrity and is tightly linked to the development of cancer. A...
BRAF Mutations, Survival, and Recurrence in Patients Undergoing Surgery for Colorectal Cancer Liver Metastases
In a study reported in JAMA Surgery, Margonis et al found that presence of a BRAF V600E mutation was associated with higher risk of recurrence and poorer overall survival among patients undergoing surgical resection of liver metastases from colorectal cancer. Study Details The cohort study...
Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma
In a report from the diffuse intrinsic pontine glioma (DIPG) registries of the International and European Societies for Pediatric Oncology, published in the Journal of Clinical Oncology, Hoffman et al identified characteristics of long-term survivors among pediatric and young adult...
Trametinib Treatment for Histiocytic Sarcoma With an Activating MAP2K1 Mutation
In a letter to the editor in The New England Journal of Medicine, Gounder et al described the successful treatment of a patient with histiocytic sarcoma and an activating MAP2K1 (MEK1) mutation with the MAPK kinase 1 and 2 inhibitor trametinib (Mekinist). As noted by the authors, patients with...
High–Nicotine-Dependent Smokers Less Likely to Quit After Lung Cancer Screening
A new study by Rojewski et al in CHEST investigated the relationships between the degree of nicotine dependence and both the likelihood of successfully quitting smoking and clinical outcomes in a cohort of screened patients. The study found that patients with a higher nicotine dependence...
FDA Identifies Efficacy Issue in Clinical Trials of Pembrolizumab or Atezolizumab as Monotherapy in Urothelial Cancer With Low Expression of PD-L1
On May 18, the U.S. Food and Drug Administration (FDA) alerted health-care professionals, oncology clinical investigators, and the public about decreased survival associated with the use of pembrolizumab (Keytruda) or atezolizumab (Tecentriq) as monotherapy in clinical trials to treat patients with ...
Antoni Ribas, MD, Recognized for Research in Cancer Immunology
Antoni Ribas, MD, Professor of Medicine and Director of the Tumor Immunology Program at the University of California Jonsson Comprehensive Cancer Center, has been awarded the sixth American Association of Cancer Research–Cancer Research Institute Lloyd J. Old Award in Cancer Immunology. The award...
Treatment of Malignant Pleural Mesothelioma: ASCO Clinical Practice Guideline
As reported by Hedy L. Kindler, MD, of the University of Chicago, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on the treatment of malignant pleural mesothelioma.1 The guideline was based on a systematic literature search and expert panel...
Logistics of CAR T-Cell Therapy in Real-World Practice
With the U.S. Food and Drug Administration (FDA) approvals of tisagenlecleucel (Kymriah)1 and axicabtagene ciloleucel (Yescarta),2 chimeric antigen receptor (CAR) T-cell therapy has moved into real-world practice, offering new potentially curative options for incurable hematologic malignancies. Its ...
For James Allison, PhD, Perseverance and Hard Science Are Paramount in Cancer Research
For this installment in the Living a Full Life series of articles, guest editor Jame Abraham, MD, interviewed immunology pioneer James Allison, PhD, Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research,...
Focus on the Tennessee Oncology Practice Society
The Tennessee Oncology Practice Society (TOPS) is among the oldest and one of many politically active ASCO State Affiliates. Founded in 1990, the organization has since been a voice for Tennessee’s diverse community of oncology professionals, advocating for patient access to the best available care ...
Treating Insomnia in Cancer Survivors
A Patient-Centered Outcomes Research Institute–supported randomized clinical trial of cancer survivors showed that 8 weeks of either acupuncture or cognitive behavioral therapy for insomnia (CBT-I) decreased the severity of insomnia among cancer survivors, though improvements were greatest among...
Molecular Minimal Residual Disease Detection Shows Further Promise in Acute Myeloid Leukemia
Extended next-generation sequencing genomic profiling in acute myeloid leukemia (AML) has revealed remarkable heterogeneity and molecular complexity of the disease and provided critical insights into the genetic mechanisms underpinning of preleukemic and leukemic pathogenesis.1,2 Despite...
Survival in Male vs Female Patients Receiving Immune Checkpoint Inhibitors
In a systematic review and meta-analysis reported in The Lancet Oncology, Conforti et al found a significant difference in overall survival benefit favoring male vs female patients receiving immune checkpoint inhibitor therapy for advanced cancers. Study Details The study involved database...
PET-Guided Therapy for Aggressive Non-Hodgkin Lymphomas
In a German phase III trial (PETAL) reported in the Journal of Clinical Oncology, Dührsen et al found that interim 18F-FDG positron emission tomography (PET) findings were associated with survival in patients with aggressive non-Hodgkin lymphomas receiving R-CHOP (rituximab [Rituxan]...
Circulating Tumor Cells and Benefit of Adjuvant Radiotherapy in Early Breast Cancer
In a study reported in JAMA Oncology, Goodman et al found that adjuvant radiotherapy was associated with better outcome in patients with early breast cancer who had detectable circulating tumor cells (CTCs). Study Details The analysis included data from patients with stage pT1 to pT2 and pN0 to...
PARP Inhibitor Shows Promise in Patients With BRCA-Mutated Pancreatic Cancer
A targeted therapy that has been effective in fighting ovarian cancer in women, including those with BRCA1 and BRCA2 mutations, may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options. An international team of researchers was...
Childhood Cancer STAR Act Approved by Senate and House
On May 22, the Childhood Cancer Survivorship Treatment Access and Research (STAR) Act was passed by the Senate and House and is now being sent to President Donald Trump to be signed into law. As the most comprehensive childhood cancer bill ever introduced to Congress, the Childhood Cancer STAR Act...
Targeted Sequencing Detection of Molecular Minimal Residual Disease and Prognosis in Acute Myeloid Leukemia
In a study reported in The New England Journal of Medicine, Mojca Jongen-Lavrencic, MD, PhD, of Erasmus MC Cancer Institute, and colleagues found that molecular minimal residual disease identified by next-generation sequencing during complete remission was associated with an increased risk of...
Once-Weekly vs Every-3-Week Cisplatin Chemoradiation in Locally Advanced Head and Neck Cancer
In an Indian phase III trial reported in the Journal of Clinical Oncology, Vanita Noronha, MD, of Tata Memorial Hospital, Mumbai, and colleagues found that curative-intent adjuvant chemoradiation with cisplatin at 100 mg/m2 every 3 weeks produced better locoregional control vs cisplatin at 30...
NCCN Names Wui-Jin Koh, MD, New Chief Medical Officer
The National Comprehensive Cancer Network® (NCCN®) has named Wui-Jin Koh, MD, as Senior Vice President, Chief Medical Officer, a newly created position. Dr. Koh will add additional physician representation at NCCN headquarters, which includes Chief Executive Officer Robert W. Carlson, MD. Dr. Koh...
How a Recent Study Heats up the Debate Over Intraperitoneal Chemotherapy in Newly Diagnosed Advanced Ovarian Cancer
Based on pharmacokinetic and preclinical data, there appears to be a biologic advantage to the use of intraperitoneal chemotherapy in treating some malignancies confined to the abdomen. Since most ovarian, fallopian tube, and peritoneal cancers present and recur in the peritoneal cavity, this...
The American Society of Clinical Oncology at a Glance
The American Society of Clinical Oncology (ASCO) held its first scientific Annual Meeting on April 9, 1965, in the Bellevue Stratford Hotel in Philadelphia. More than 70 members and invited guests attended the inaugural event, which featured three presentations on leukemia and multiple myeloma. The ...
Adding Hyperthermic Intraperitoneal Chemotherapy to Cytoreductive Surgery Improves Outcomes in Advanced Ovarian Cancer
In a Dutch/Belgian phase III trial reported in The New England Journal of Medicine by Willemien J. van Driel, MD, PhD, of the Netherlands Cancer Institute, and colleagues, the addition of hyperthermic intraperitoneal chemotherapy (aka HIPEC) to interval cytoreductive surgery following neoadjuvant...
A Lifetime of Accomplishments in Oncology Brings Knighthood to Sir Murray F. Brennan, MD, FACS
Sir Murray F. Brennan, MD, FACS, was born on April 2, 1940, in Auckland, New Zealand, which lies on and around an isthmus surrounded by the sparkling azure waters of the Hauraki Gulf. “I was born at the beginning of World War II. Fortunately, my father was too old to be drafted into the army. I...
Update on ATLAS Trial of Axitinib for RCC Recurrence Risk
Pfizer recently announced that the independent data monitoring committee for the phase III ATLAS trial, which is evaluating axitinib (Inlyta) as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy, recommended stopping the trial at a planned interim...
ASCO Honors Leaders in Cancer Care With 2018 Special Awards
ASCO AND ASCO’s Conquer Cancer Foundation recognized winners of ASCO’s 2018 Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards during the 2018 ASCO Annual Meeting, June 1 to June 4, in Chicago. The recipients of these awards included researchers, patient advocates, and...
Register Now for the ASCO Research Community Forum 2018 Annual Meeting
Register now to join research colleagues from across the United States at the ASCO Research Community Forum Annual Meeting. The meeting offers physician researchers and research staff from a variety of programs a unique platform to collaborate and develop solutions to common challenges with...
Nancy L. Bartlett, MD, Moved From Engineering to Medicine After a Stint in the ER
Nationally recognized oncologist Nancy L. Bartlett, MD, had an early love for mathematics and a swooning aversion to the sight of blood. “I was born and reared in Kansas City, Missouri and am a Midwesterner at heart. No one in the family was involved in medicine. My mom was an elementary school...
A Commitment to Innovation, Gender Equality, and Family Legacy Inspire Endowed Young Investigator Award Gifts for ASCO’s Conquer Cancer Foundation
Individuals, foundations, and corporations continue to fuel the brightest minds in cancer research through lifetime investments in the Conquer Cancer Grants & Awards program. The roster of endowed Young Investigator Awards (YIA) grew by three in 2018, with awards gifted by Thomas G. Roberts,...
